National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Rivaroxaban 10mg daily for the prevention of recurrent venous thromboembolism in patients who have completed at least 6 months anticoagulation therapy for DVT or PE.

NCPE Assessment Process Complete
Rapid review received 20/11/2017
Rapid review completed 21/11/2017
Rapid Review outcome Full pharmacoeconomic assessment recommended

The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.